Kura Oncology (KURA) insider files to sell 1,813 Rule 144 shares

Rhea-AI Filing Summary

Kura Oncology insider plans a small stock sale under Rule 144. A shareholder intends to sell 1,813 shares of Kura Oncology common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $15,356.11.

The filing states that 88,309,441 shares of common stock were outstanding. The shares to be sold were acquired from the issuer as restricted stock units (RSUs) on January 27, 2026, the same date targeted for the sale.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1813	15356.11	88309441	01/27/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/27/2026	RSU	Issuer			1813	01/27/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does KURA’s latest Form 144 filing disclose?

The Form 144 shows a Kura Oncology shareholder plans to sell 1,813 common shares. The shares have an aggregate market value of $15,356.11 and are expected to be sold on NASDAQ through Morgan Stanley Smith Barney LLC.

How many Kura Oncology (KURA) shares are covered by this planned sale?

The notice covers a proposed sale of 1,813 Kura Oncology common shares. These shares were recently acquired as RSUs from the issuer and are being registered for potential resale under Rule 144 through a brokerage transaction.

What is the aggregate market value of KURA shares in this Form 144?

The filing reports an aggregate market value of $15,356.11 for the 1,813 Kura Oncology shares. This value reflects the estimated market price used in the notice for the planned NASDAQ sale via Morgan Stanley Smith Barney LLC.

When were the Kura Oncology (KURA) shares acquired and how?

The 1,813 Kura Oncology shares were acquired on January 27, 2026 through an RSU (restricted stock unit) transaction from the issuer. The same date is listed as the payment date, with the nature of payment described as “N/A.”

How many Kura Oncology (KURA) shares were outstanding according to the Form 144?

The notice states that 88,309,441 Kura Oncology common shares were outstanding. This figure provides context for the size of the planned 1,813-share sale relative to the company’s total common stock base.

Which broker will handle the planned KURA share sale under Rule 144?

The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services, at One New York Plaza, as the broker. The planned sale of 1,813 Kura Oncology common shares is expected to occur on the NASDAQ exchange.